Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,684.86
(
-0.47%
)
US TECH 100
24,004.40
(
-0.53%
)
Dow Jones
46,642.83
(
-0.75%
)
Brent Oil
105.66
(
4.97%
)
Bitcoin
71,211.68
(
-3.69%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: floblu14 post# 132597

Tuesday, 06/25/2013 9:34:31 AM

Tuesday, June 25, 2013 9:34:31 AM

Post# of 257253
USPTO issues sialylation patent licensed to MNTA:

http://finance.yahoo.com/news/momenta-pharmaceuticals-announces-issuance-u-123000304.html

Momenta Pharmaceuticals…today announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 8,470,318, entitled "Polypeptides With Enhanced Anti-inflammatory and Decreased Cytotoxic Properties and Related Methods," to The Rockefeller University. Momenta is the exclusive licensee of the patent. The patent claims methods of inhibiting inflammation using intravenous immunoglobulin (IVIG)-derived, sialylated Fc regions and expires in 2028.

This is the IP protection MNTA needed to continue pursuing the sialylated-IVIG program.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now